Article Text

PDF
Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke

Statistics from Altmetric.com

R L Sacco

Dr R L Sacco, University of Miami, Miami, FL, USA; rsacco@med.miami.edu

STUDY DESIGN

Design:

randomised controlled trial with 2 × 2 factorial design (Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]). ClinicalTrials.gov NCT00153062.

Allocation concealment:

concealed.*

Blinding:

{blinded (patients, clinicians, data collectors, outcome assessors, safety committee, and data analysts)}†.*

STUDY QUESTION

Setting:

695 centres in 35 countries worldwide.

Patients:

20 332 patients ⩾50 years of age (mean age 66 y, 64% men) who had had an ischaemic stroke in the previous 120 days and were clinically and neurologically stable.

Intervention:

aspirin, 25 mg, plus extended-release dipyridamole (ERDP), 200 mg, twice daily (n = 10 181) or clopidogrel, 75 mg, once daily (n = 10 151). Patients were also randomised to telmisartan or placebo (see Yusuf abstract).

Outcomes:

recurrent stroke of any type, a composite end point (stroke, myocardial infarction, or death from vascular causes), and major bleeding. The trial had >82% power to reject the inferiority null hypothesis with a non-inferiority margin for the hazard ratio of 1.075.

Follow-up period:

mean 2.5 years.

Patient follow-up:

99% (intention-to-treat analysis).

MAIN RESULTS

Rates of recurrent stroke were similar in the aspirin …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.